Genenta Science S.p.A. (NASDAQ:GNTA) Sees Large Increase in Short Interest

Genenta Science S.p.A. (NASDAQ:GNTA) was the target of a large growth in short interest in December. As of December 15th, there was short interest totalling 3,100 shares, a growth of 121.4% from the November 30th total of 1,400 shares. Based on an average daily volume of 13,600 shares, the days-to-cover ratio is currently 0.2 days.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Genenta Science in a research note on Wednesday, October 2nd.

Genenta Science Price Performance

GNTA stock traded down $0.05 during mid-day trading on Friday, reaching $4.94. 605 shares of the company traded hands, compared to its average volume of 9,665. Genenta Science has a fifty-two week low of $2.20 and a fifty-two week high of $7.28. The firm’s 50 day moving average price is $5.11 and its 200 day moving average price is $4.41.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Genenta Science stock. AlTi Global Inc. acquired a new position in shares of Genenta Science S.p.A. (NASDAQ:GNTA) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 200,288 shares of the company’s stock, valued at approximately $621,000. AlTi Global Inc. owned about 1.10% of Genenta Science at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.13% of the company’s stock.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.